3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
8
NIH
4
NETWORK
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Conditions
Leukemia, Myeloid, Acute
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Myelodysplastic Syndromes
2
Melanoma
2
Leukemia, Promyelocytic, Acute
2
Leukemia
2
Hematologic Neoplasms
2
Small Cell Lung Carcinoma
1
Primary Myelofibrosis
1
Neoplasms
1
Hematologic Diseases
1
Interventions
Cytarabine
21
Imatinib Mesylate
20
venetoclax
16
Azacitidine
16
nilotinib
15
Cyclophosphamide
15
fludarabine
13
Dasatinib
12
blinatumomab
10
Rituximab
10
quizartinib
7
Gemtuzumab
7
Daunorubicin
7
ruxolitinib
6
Drug Therapy
6
Clofarabine
6
Bendamustine Hydrochloride
6
AP 1903 reagent
6
ponatinib
5
fludarabine phosphate
5
Whole-Body Irradiation
5
Vincristine
5
Mycophenolic Acid
5
Methotrexate
5
Granulocyte Colony-Stimulating Factor
5
Dexamethasone
5
vosaroxin
4
revumenib
4
rasburicase
4
forodesine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia
×
Tretinoin
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled
NCT07296445
2025-12-29
LATITUDE
SDK Therapeutics, Inc.
Phase 3
Not yet recruiting
120 enrolled